Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Nefrología (Madrid)
versión On-line ISSN 1989-2284versión impresa ISSN 0211-6995
Resumen
PASCUAL, Julio et al. Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities. Nefrología (Madr.) [online]. 2017, vol.37, n.3, pp.253-266. ISSN 1989-2284. https://dx.doi.org/10.1016/j.nefro.2016.11.007.
The immunosuppressive combination most commonly used in de novo kidney transplantation comprises a calcineurin inhibitor (CI), tacrolimus, a mycophenolic acid derivative and steroids. The evidence which underlies this practice is based in the Symphony trial with controlled follow-up of one year, in which no comparator group included the combination CI-mTOR inhibitor. Different high-quality clinical trials support the use of everolimus as a standard immunosuppressive drug associated with reduced exposure of a CI in kidney transplantation. This combination could improve health related outcomes in kidney transplantation recipients.
The present recommendations constitute an attempt to summarise the scientific evidence supporting this practice, discuss false beliefs, myths and facts, and offer specific guidelines for safe use, avoiding complications.
Palabras clave : Kidney transplant; Everolimus; mTOR inhibitors.